SCHEMBL22014468

SCHEMBL22014468

C[C@H](O)CN1CCN(Cc2ccc(C(=O)NC(Cc3ccccc3)C(=O)O)cc2)CCN(C[C@H](C)O)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 3/20 0.57
HDAC1 Q13547 3/20 0.57
KCNH2 Q12809 2/20 0.57
PTPN1 P18031 2/20 0.56
ALDH1A1 P00352 3/20 0.55
CA2 P00918 3/20 0.54
CA1 P00915 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ACE P12821 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ITGB1 P05556 1/20 0.48
ITGA4 P13612 1/20 0.48
ITGB7 P26010 1/20 0.48
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22014462 0.88 HDAC1 (0.51) HDAC4HDAC1KCNH2CA2CA1
SCHEMBL22014470 0.87 HDAC1 (0.50) HDAC4HDAC1KCNH2CA2CA1
SCHEMBL22297685 0.85 ALDH1A1 (0.61) HDAC4HDAC1KCNH2PTPN1ALDH1A1
SCHEMBL24672242 0.78 KDM4E (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1394539 0.78 KDM4E (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1394677 0.78 KDM4E (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1394535 0.78 KDM4E (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL21797152 0.78 KDM4E (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23486230 0.77 ALDH1A1 (0.56) HDAC4HDAC1KCNH2PTPN1ALDH1A1
SCHEMBL10903263 0.77 HDAC1 (0.52) HDAC4HDAC1KCNH2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204065-A1 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-09-29 WO disclosed
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-05-31 US disclosed
WO-2020102820-A1 COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups SLC40A1, TAC3, ABCB7 HDAC4 1404/4885HDAC1 785/4885KCNH2 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.